Trevena Post Op Pain Management Drug Cuts Hospital Stay Length Vs. Patients On Opioids

Trevena Inc TRVN announced initial topline OLINVYK data from two related real-world outcomes studies: VOLITION and ARTEMIS.
The VOLITION study (n=203 patients) assessed the potential impact of OLINVYK on respiratory, gastrointestinal (GI), and cognitive function outcomes in the postoperative setting. Initial GI and cognition data are available, with respiratory outcome data expected in mid-2023.
OLINVYK-treated patients had a 52.2% GI complete responder rate, defined as no vomiting and no antiemetic use throughout the postoperative period.
Over 90% of OLINVYK-treated patients reported feeling "alert and calm" from the morning of the first postoperative day.
Only 3.9% of OLINVYK-treated patients exhibited symptoms suggestive of delirium at any point in the 48-hour postoperative observation point.
The ARTEMIS study was an electronic medical record (EMR) based assessment focused on clinical and health resource utilization outcomes. Initial ARTEMIS data from Wake Forest Baptist Health is currently available, representing 96 OLINVYK-treated patients and 457 matched patients treated with other IV opioids.
OLINVYK-treated patients had a statistically significant 1.6-day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids.
Trevena reported a year-end cash balance Of $38.3 million, providing a cash runway into Q4 2023.
Price Action: TRVN shares are up 4.93% at $0.7661 on the last check Thursday.

Earnings Calendar